354 related articles for article (PubMed ID: 38696033)
1. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.
Tecik M; Adan A
Curr Treat Options Oncol; 2024 May; ():. PubMed ID: 38696033
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.
Tecik M; Adan A
Onco Targets Ther; 2022; 15():1449-1478. PubMed ID: 36474506
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor of activated T-cells, NFATC1, governs FLT3
Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
[TBL] [Abstract][Full Text] [Related]
7. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
8. Quizartinib (AC220): a promising option for acute myeloid leukemia.
Zhou F; Ge Z; Chen B
Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
[TBL] [Abstract][Full Text] [Related]
9. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells.
Darici S; Zavatti M; Braglia L; Accordi B; Serafin V; Horne GA; Manzoli L; Palumbo C; Huang X; Jørgensen HG; Marmiroli S
Adv Biol Regul; 2021 Dec; 82():100830. PubMed ID: 34555701
[TBL] [Abstract][Full Text] [Related]
11. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
12. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.
Garg M; Nagata Y; Kanojia D; Mayakonda A; Yoshida K; Haridas Keloth S; Zang ZJ; Okuno Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ding LW; Alpermann T; Sun QY; Lin DC; Chien W; Madan V; Liu LZ; Tan KT; Sampath A; Venkatesan S; Inokuchi K; Wakita S; Yamaguchi H; Chng WJ; Kham SK; Yeoh AE; Sanada M; Schiller J; Kreuzer KA; Kornblau SM; Kantarjian HM; Haferlach T; Lill M; Kuo MC; Shih LY; Blau IW; Blau O; Yang H; Ogawa S; Koeffler HP
Blood; 2015 Nov; 126(22):2491-501. PubMed ID: 26438511
[TBL] [Abstract][Full Text] [Related]
13. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
[TBL] [Abstract][Full Text] [Related]
14. Which FLT3 Inhibitor for Treatment of AML?
Senapati J; Kadia TM
Curr Treat Options Oncol; 2022 Mar; 23(3):359-380. PubMed ID: 35258791
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
17. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
[TBL] [Abstract][Full Text] [Related]
18. GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
Xiao X; Wang P; Zhang W; Wang J; Cai M; Jiang H; Wu Y; Shan H
Cancer Cell Int; 2023 Nov; 23(1):302. PubMed ID: 38037057
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
